A couple thoughts. First, the gut concentrations for anti-inflammatory, immunomodulatory and wound healing effects of Brilacidin may be lower than the MIC for E. coli. As you know, Brilacidin is predominantly for gram positive organisms with modest gram negative coverage. My recollection is that E. coli had a higher MIC than the gram positives studied. I'm sure IPIX has a sense for the potential cidal effect on the gut biome and has a read on the concentrations necessary for anti-inflammatory, immunomodulatory and wound healing effects. Also, as I believe we will see from top line B-OM, it doesn't take long-term continuous Brilacidin exposure for an anti-inflammatory response.
News 
Market Data 
Discover 
AI
